# OnCo record sirolimus-albumin-bound (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/sirolimus-albumin-bound/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "sirolimus-albumin-bound" ;
  schema:name "Sirolimus protein-bound particles"@en ;
  schema:alternateName "nab-sirolimus"@en, "ABI-009"@en, "Nanoparticle albumin-bound rapamycin"@en, "Fyarro" ;
  schema:description "Fyarro is an infusion of the transplant drug sirolimus packaged in albumin particles. It is the first approved treatment for malignant PEComa, a rare soft-tissue tumour driven by loss of the TSC genes."@en ;
  schema:url <https://onco.cc/drugs/sirolimus-albumin-bound/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Sirolimus> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=sirolimus%20protein-bound>, <https://www.cancer.gov/about-cancer/treatment/drugs/sirolimus-protein-bound-particles> ;
  onco:status "approved" ;
  onco:tag "nci-list" ;
  onco:modality "Albumin-bound mTOR inhibitor (intravenous)" ;
  onco:approval "US 2021: Locally advanced unresectable or metastatic malignant PEComa" ;
  onco:related <https://onco.cc/drugs/everolimus/>, <https://onco.cc/drugs/temsirolimus/> ;
  onco:cancers <https://onco.cc/cancers/sarcoma/>, <https://onco.cc/cancers/pecoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/mtor/> ;
  onco:companies <https://onco.cc/companies/aadi-bioscience/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:trials <https://onco.cc/trials/nct05997017/>, <https://onco.cc/trials/nct05103358/> .